Latest Cancer News

Calquence Improves Survival in Relapsed Chronic Lymphocytic Leukemia (05-20-2019)
An interim analyses of the phase 3 “ASCEND” clinical trial evaluating single-agent Calquence (acalabrutinib) compared to Rituxan (rituximab) plus idelasib or bendamustine in recurrent chronic lymphocytic... Continue Reading

Zytig Treatment Prolongs Survival in Advanced Prostate Cancer (05-7-2019)
Zytig (Abiraterone acetate) plus prednisone and androgen deprivation therapy (ADT) significantly extends overall survival compared with placebo plus ADT in men with newly diagnosed high-risk metastatic... Continue Reading

FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation (05-7-2019)
On May 2, 2019, the Food and Drug Administration approved ivosidenib (TIBSOVO, Agios Pharmaceuticals, Inc.) for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected... Continue Reading

More Cancer News

Patient Resources

VirtualTour_280x99

CoC Logo 541 ACCREDITED PROGRAM caps